Niagen Bioscience (OCD1) Stock Overview
Operates as a bioscience company engages in developing healthy aging products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OCD1 passed our risk checks.
OCD1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Niagen Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.15 |
| 52 Week High | US$12.40 |
| 52 Week Low | US$4.72 |
| Beta | 2.31 |
| 1 Month Change | -6.36% |
| 3 Month Change | -8.85% |
| 1 Year Change | -1.90% |
| 3 Year Change | 198.46% |
| 5 Year Change | 26.85% |
| Change since IPO | 123.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCD1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.5% | 0.9% | 1.0% |
| 1Y | -1.9% | -5.4% | 15.1% |
Return vs Industry: OCD1 exceeded the German Life Sciences industry which returned -5.4% over the past year.
Return vs Market: OCD1 underperformed the German Market which returned 15% over the past year.
Price Volatility
| OCD1 volatility | |
|---|---|
| OCD1 Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: OCD1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OCD1's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 104 | Rob Fried | www.niagenbioscience.com |
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products.
Niagen Bioscience, Inc. Fundamentals Summary
| OCD1 fundamental statistics | |
|---|---|
| Market cap | €427.23m |
| Earnings (TTM) | €17.44m |
| Revenue (TTM) | €106.44m |
Is OCD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCD1 income statement (TTM) | |
|---|---|
| Revenue | US$124.71m |
| Cost of Revenue | US$45.03m |
| Gross Profit | US$79.68m |
| Other Expenses | US$59.25m |
| Earnings | US$20.43m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 63.89% |
| Net Profit Margin | 16.38% |
| Debt/Equity Ratio | 0% |
How did OCD1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 06:47 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Niagen Bioscience, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |